SGLT2 억제제 시장 규모, 점유율, 동향 분석 보고서 : 약물별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

SGLT2 억제제 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 SGLT2 억제제 세계 시장 규모는 2030년까지 294억 3,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 7.71% 성장할 것으로 예상됩니다.

미국당뇨병학회(ADA), 유럽당뇨병학회(EASD), 유럽심장학회(ESC) 등 주요 의료기관의 권고 및 지지 가이드라인은 혈당 조절을 넘어 나트륨-포도당 공수송체 2(SGLT2) 억제제를 지지하고 있습니다. 예를 들어, 2023년 8월 유럽심장학회(ESC)는 2021년 이후 시행된 약 12개의 새로운 임상시험인 EMPEROR-Preserved, DELIVER, STRONG-HF, IRONMAN 등의 연구 결과를 통합하여 심부전 가이드라인을 업데이트하는 내용을 발표했습니다. ESC Congress 2023에서 발표된 최신 가이드라인은 경증 심박출량 감소 심부전(HFmrEF) 환자 치료 시 SGLT2 억제제 사용에 대한 새로운 권고사항을 담고 있습니다.

그리고 향후 몇 년 동안 투석이 필요한 환자 수가 증가함에 따라 CKD 환자 치료에 SGLT2 억제제와 같은 의약품에 대한 수요가 높아질 것으로 예상되며, 2023년 11월 NICE(National Institute for Health and Care Excellence)는 만성콩팥병(CKD) 환자에게 SGLT2 억제제 엠파글리플로진(Empagliflozin)의 사용을 권장하는 가이드라인을 발표했습니다. 엠파글리플로진은 신부전 진행을 지연시키고 심장마비 및 뇌졸중 위험을 감소시키는 효과가 입증되었으며, NICE는 모든 단계의 만성콩팥병 환자에게 엠파글리플로진 치료를 제공할 것을 권고하고 있습니다. 이러한 의약품 규제기관의 권고사항은 예측 기간 동안 의약품 수요를 증가시킬 것으로 예상됩니다.

노년층은 제2형 당뇨병과 심부전에 걸리기 쉬우며, 약물이 큰 효과를 보이는 질환입니다. 이러한 인구 통계학적 변화로 인해 SGLT2 억제제와 같은 효과적인 치료제에 대한 수요가 증가하고 있으며, SGLT2 억제제는 특히 노년층에서 흔히 발생하는 심혈관 및 신장 위험을 감소시키는 데 효과적입니다. 이러한 장점으로 인해 고령 환자들에게 선호되는 약물이 되고 있습니다. 세계보건기구(WHO)에 따르면, 2022년에는 약 14억 명이 60세 이상의 노인 인구가 될 것이며, 이는 2020년의 10억 명에서 증가할 것으로 예상됩니다. 또한 WHO는 노인 인구가 21억 명에 달할 것으로 예측하고 있습니다. 이처럼 노인 인구의 증가는 SGLT2 억제제에 대한 세계 수요를 증가시켜 시장 성장을 촉진할 것으로 예상됩니다.

당뇨병에 대한 환자와 의료진 모두에서 SGLT2 억제제가 당뇨병에 대한 인식과 치료의 중요성이 높아짐에 따라 처방률 향상에 기여하고 있습니다. 예를 들어, 세계보건기구(WHO)는 2021년 SGLT2 억제제와 인슐린을 포함한 당뇨병 치료제에 대한 인지도를 높이고 환자 접근성을 개선하기 위해 '세계 당뇨병 콤팩트(Global Diabetes Compact)' 이니셔티브를 출범했습니다. 이러한 이니셔티브는 SGLT2 억제제의 채택을 촉진하고 예측 기간 동안 시장에 새로운 기회를 열어줄 것으로 예상됩니다.

SGLT2 억제제 시장 보고서 하이라이트

• 저혈당(엠파글리플로진) 부문은 2023년 시장을 장악하고 예측 기간 동안 크게 성장할 것으로 예상됩니다. 이러한 성장은 당뇨병, 만성콩팥병, 심혈관 질환의 유병률 증가와 치료에 대한 높은 약물 수요에 기인합니다.
• 2023년에는 제 2형 당뇨병 부문이 시장을 장악했습니다. 이러한 우위는 당뇨병 유병률 증가, 노인 인구 증가, 약물 처방률 증가에 기인합니다.
• 병원 약국 부문이 2023년 시장을 장악했습니다. 이 우위는 당뇨병, CKD 및 심부전 환자의 진단 및 치료를 위한 입원 건수 증가에 기인합니다.
• 북미는 높은 수준의 의료 인프라, 대상 질환의 유병률 증가, 양호한 규제 환경 등의 요인으로 인해 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 SGLT2 억제제 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• SGLT2 억제제 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석
  • 대상 인구 분석

제4장 SGLT2 억제제 시장 : 약제별 추정·동향 분석

• 세계의 SGLT2 억제제 시장 : 약제별 대시보드
• 세계의 SGLT2 억제제 시장 : 약제별 변동 분석
• 세계의 SGLT2 억제제 시장 : 약제별 매출
• Jardiance (empagliflozin)
• Farxiga (dapagliflozin)
• Invokana (canagliflozin)
• Inpefa (sotagliflozin)
• Qtern (dapagliflozin/saxagliptin)
• 기타 SGLT2 억제제

제5장 SGLT2 억제제 시장 : 적응증별 추정·동향 분석

• 세계의 SGLT2 억제제 시장 : 적응증별 대시보드
• 세계의 SGLT2 억제제 시장 : 적응증별 변동 분석
• 세계의 SGLT2 억제제 시장 : 적응증별 매출
• 2형 당뇨병
• 심혈관
• 만성 신장병(CKD)
• 기타

제6장 SGLT2 억제제 시장 : 유통 채널별 추정·동향 분석

• 세계의 SGLT2 억제제 시장 : 유통 채널별 대시보드
• 세계의 SGLT2 억제제 시장 : 유통 채널별 변동 분석
• 세계의 SGLT2 억제제 시장 : 유통 채널별 매출
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 SGLT2 억제제 시장 : 약제, 적응증, 유통 채널별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018년에서 2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 상황

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석, 2023년
  • Boehringer Ingelheim International GmbH.
  • AstraZeneca
  • Merck &Co., Inc.
  • Johnson & Johnson Services, Inc.(Janssen Pharmaceuticals, Inc.)
  • TheracosBio, LLC
  • Lexicon Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Ltd

ksm

영문 목차

영문목차

SGLT2 Inhibitors Market Growth & Trends:

The global SGLT2 inhibitors market size is anticipated to reach USD 29.43 billion by 2030 and is expected to expand at a CAGR of 7.71% during the forecast period, according to a new report by Grand View Research, Inc. The recommendations and supportive guidelines from major health organizations, such as the American Diabetes Association (ADA), the European Association of for the Study of Diabetes (EASD), the European Society of Cardiology (ESC), and others have endorsed sodium-glucose cotransporter-2 (SGLT2) inhibitors for them beyond glucose control. For instance, in August 2023, the European Society of Cardiology (ESC) has issued a focused update to their heart failure guidelines, integrating findings from nearly a dozen new clinical trials since 2021, such as EMPEROR-Preserved, DELIVER, STRONG-HF, and IRONMAN. Released at the ESC Congress 2023, the updated guidelines introduce new recommendations for the use of SGLT2 inhibitors in treating patients with heart failure with mildly reduced ejection fraction (HFmrEF).

In addition, the growing number of patients needing dialysis over the next few years showcased high demand of medicines such as SGLT2 inhibitors for treatment of CKD patients. In November 2023, the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of empagliflozin, an SGLT2 inhibitor, for patients with chronic kidney disease (CKD). Empagliflozin has demonstrated efficacy in slowing the progression to kidney failure and reducing the risk of heart attacks and strokes. NICE recommends making this treatment available to patients across all stages of CKD. Such recommendations from drug regulatory agencies are expected to boost demand for drugs during the forecast period.

The elder adults are more prone to type 2 diabetes and heart failure, conditions where drugs have shown substantial benefits. This demographic shift increases the demand for effective treatments such as SGLT2 inhibitors. SGLT2 inhibitors are beneficial in reducing cardiovascular and renal risks, which are particularly prevalent in the elderly. This advantage makes these medications a preferred choice for older patients. According to the World Health Organization (WHO), in 2022, around 1.4 billion people were aged 60 years and over, which was raised from 1 billion in 2020. In addition, WHO estimates that the elderly population is expected to reach 2.1 billion. Thus, rising geriatric population is expected to boost demand for SGLT2 inhibitors worldwide and drive market growth.

Increasing awareness of diabetes and significance of SGLT2 inhibitors in treatment among both patients and healthcare providers contribute to higher prescription rates. For instance, in 2021, the WHO launched initiative "Global Diabetes Compact" to raise awareness and improve patient access to diabetic medicine including SGLT2 inhibitors and insulin. Such initiatives are expected to boost adoption of SGLT2 inhibitors and open new opportunities in the market over the forecast period.

SGLT2 Inhibitors Market Report Highlights:

• Jardiance (empagliflozin) segment dominated the market in 2023 and is anticipated to grow significantly over the forecast period. This growth is attributed due to increasing prevalence of diabetes, CKD, and cardiovascular conditions and high drug demand for treatment
• Type 2 diabetes segment dominated the market in 2023. This dominance is attributed due to rising incidence of diabetes, increasing geriatric population, and increased prescription rate of drug
• Hospital pharmacies segment dominated the market in 2023. This dominance is attributed due to increasing number hospitalization of diabetes, CKD, and heart failure patients for diagnosis and treatment
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising prevalence of target diseases, and favorable regulatory environment

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug and Indication outlook
  • 2.2.2. Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of target disease
    • 3.2.1.2. Technological advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of drug development
    • 3.2.2.2. Stringent regulatory policies for drug approval
• 3.3. SGLT2 Inhibitors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

• 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
• 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
• 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
• 4.4. Jardiance (empagliflozin)
  • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Farxiga (dapagliflozin)
  • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Invokana (canagliflozin)
  • 4.6.1. Invokana (canagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Inpefa (sotagliflozin)
  • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Qtern (dapagliflozin/saxagliptin)
  • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Other SGLT2 Inhibitors
  • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

• 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
• 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
• 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
• 5.4. Type 2 Diabetes
  • 5.4.1. Type 2 diabetes market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Cardiovascular
  • 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Chronic Kidney Disease (CKD)
  • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
• 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
• 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Boehringer Ingelheim International GmbH.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. AstraZeneca
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. TheracosBio, LLC
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Lexicon Pharmaceuticals, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Eli Lilly and Company
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Bristol-Myers Squibb Company
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Glenmark Pharmaceuticals Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives

관련자료